Our Technology
GenoME Diagnostics identifies DNA methylation changes in both tissue and liquid biopsies, and measures these changes on a cutting edge, droplet digital PCR platform. This type of PCR platform offers unrivalled sensitivity and precision compared to the traditional types of PCR. We will look to expand our portfolio beyond ovarian cancer, both in house, and externally through partnership and collaboration, and as a service to external customers.
Current projects
OvaME
Our lead product, OvaME, is in development and validation stages. It measures the levels of patented DNA methylation markers in a blood sample, incorporating the high sensitivity of droplet digital PCR.
The current blood test available in primary healthcare – CA125 – may be elevated by several unrelated, non-cancerous conditions and is additionally only elevated in ~50% of early-stage ovarian cancers. Our mission is to improve on the inaccurate CA125 test to provide earlier ovarian cancer diagnosis, and to improve the outcomes of women affected by this aggressive disease.
Patrick G Johnston Centre
for Cancer Research
97 Lisburn Road
Belfast BT9 7AY
Northern Ireland
+44 (0)79 7205 6063
info@genomediagnostics.co.uk
